Zobrazeno 81 - 90
of 130
pro vyhledávání: '"Al-Ola Abdallah"'
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S302-S303
Context: Despite novel agents and increased better outcomes over the last years, MM is still an incurable disease marked by a relapse-remission pattern. EMD is an aggressive presentation at diagnosis and relapse for with a reported incidence of EMD i
Publikováno v:
JAMA Network Open. 4:e218084
Importance A thorough understanding of the optimal role and sequence of agents for treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol therapies in randomized clinical trials (RCTs). Objectives To examine the pro
Autor:
Maire Okoniewski, Siddhartha Ganguly, Joseph P. McGuirk, Saqib Abbasi, Ghulam Rehman Mohyuddin, Brian McClune, Al-Ola Abdallah, Leyla Shune
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S236-S237
Introduction Renal impairment is a common problem in patients with multiple myeloma (MM), and approximately 2-3% of patients develop renal impairment requiring dialysis. Autologous stem cell transplantation (ASCT) is a mainstay of treatment for eligi
Autor:
Natasa Milojkovic, Al-Ola Abdallah, Konstantinos Arnaoutakis, Mayumi Nakagawa, Samuel G. Mackintosh, Horace J. Spencer, Rodney Davis, Mohamed Kamel, Fade Mahmoud, Hannah N. Coleman, Teri Landrum, Chester Wicker
Publikováno v:
SAGE Open Medicine, Vol 6 (2018)
Objectives: Our group developed the use of the Candida skin test reagent as an adjuvant of cell-mediated immunity in designing a human papillomavirus therapeutic vaccine. Here, this technology is being applied for designing a prostate cancer immunoth
Autor:
Siddhartha Ganguly, Leyla Shune, Al-Ola Abdallah, Jordan Snyder, Hameem I Kawsar, Joseph P. McGuirk
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S295
Context: Daratumumab is an anti-CD38 monoclonal antibody used to treat plasma cell disorders. However, in clinical trials, patients with poor Eastern Cooperative Group performance status (ECOG-PS), poor renal and cardiac functions were excluded. The
Autor:
Ghulam Rehman Mohyuddin, Hameem I Kawsar, Monia Sigle, Al-Ola Abdallah, Leyla Shune, Zahra Mahmoudjafari, Joseph P. McGuirk, Atrash Shebli, Siddhartha Ganguly
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S303
Context: At this time, there is no rationale to favor a specific therapeutic class (e.g., immunomodulatory agents (IMiD), proteasome inhibitors (PI), or monoclonal antibody) over another for the treatment of relapsed/refractory myeloma (RRMM). Our in
Autor:
Al-Ola Abdallah, Angela Pennisi, Konstantinos Arnaoutakis, Paulette Mehta, Meghana Bansal, Issam Makhoul
Publikováno v:
Journal of Cancer Education. 31:736-741
Using the standardized ASCO Quality Oncology Practice Initiative (QOPI) guidelines for assessing quality cancer care, we identified communication about intent of chemotherapy as an area needing improvement in our program at the University of Arkansas
Autor:
Leyla Shune, Al-Ola Abdallah, Monia Sigle, Hameem I Kawsar, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Siddhartha Ganguly, Joseph P. McGuirk, Ajoy Dias
Publikováno v:
Journal of Clinical Oncology. 38:e20508-e20508
e20508 Background: The number of therapeutic options for patients with RRMM has increased significantly. Our institute treated a series of patients with induction therapy consisting of DPd followed by HDCT/ASCT. We present the early outcomes of these
Autor:
Peter M. Voorhees, Ira Gupta, Trisha Piontek, Hans C. Lee, Ashraf Badros, Joanna Opalinska, Roxanne C. Jewell, January Baron, Ajai Chari, Douglas W. Sborov, Axel Hoos, Sagar Lonial, Adam D. Cohen, Ajay K. Nooka, Attaya Suvannasankha, Al-Ola Abdallah, Natalie S. Callander, Eric Zhi, Suzanne Trudel, Katja Weisel
Publikováno v:
Journal of Clinical Oncology. 38:8536-8536
8536 Background: Single-agent belantamab mafodotin (B-cell maturation antigen targeting immunoconjugate) showed clinically meaningful activity and manageable safety in patients with heavily pre-treated RRMM (DREAMM-2, NCT03525678, Lancet Oncol.2020).
Autor:
Brian McClune, Leyla Shune, Osama Diab, Siddhartha Ganguly, Joseph P. McGuirk, Maire Okoniewski, Ghulam Rehman Mohyuddin, Al-Ola Abdallah
Publikováno v:
Blood. 134:5700-5700
Introduction: Autologous stem cell transplant (ASCT) followed by maintenance is the standard of care for eligible patients with multiple myeloma (MM). For patients that relapse, a second ASCT remains a viable option. However, the maintenance regimen